News | January 06, 2010

ACNM, SNM to Hold Joint Nuclear Medicine Conference

January 6, 2010 - The American College of Nuclear Medicine (ACNM) is holding its annual meeting Jan. 27-28, 2010, in Albuquerque, N.M., in conjunction with the Society of Nuclear Medicine's (SNM) Mid-Winter Meeting.

The meeting, which provides attendees with the opportunity to earn up to 25 continuing education credits, will highlight the latest advancements in molecular imaging and nuclear medicine. The educational sessions will conclude with special workshops on nanomedicine and clinical trials.

The ACNM meeting will offer presentations on PET/CT of the head and neck, including thyroid cancer, chest and abdomen. ACNM will also offer lectures on the use of molecular imaging for lung scans and brain imaging and the use of new PET radiopharmaceuticals for treating disease. For nuclear medicine and radiology residents, ACNM will offer abstract presentations and a session on how to find a job in nuclear medicine.

SNM will offer a two-day CT case review workshop that will provide 16 hours of continuing education credit for physicians. SNM will also offer workshops on the use of molecular imaging for the diagnosis of neurodegenerative disorders, and diagnosis and treatment of heart failure. Sessions will take place Jan. 29-31.

SNM's Technologist Section (SNMTS) will host "The Sharp Edges of Nuclear Medicine: See What's New," Jan. 30-31,2010, to introduce technologists to new techniques in fusion imaging, with a focus on patients with epilepsy. SNMTS will also host a joint session with the American Society of Radiologic Technologists, focusing on legislative and regulatory issues facing nuclear medicine today, including USP and the Medicare Improvement Providers and Patients Act of 2008 (MIPPA).

SNM's Molecular Imaging Center of Excellence will host its annual summit on Jan. 31 and Feb. 1. This year's summit will focus on nanomedicine and molecular imaging. More than 20 experts from a variety of fields will examine current and potential uses of nanomaterials for patient care through improved diagnosis and individualized treatment strategies.

The week will cap off with SNM's Clinical Trials Workshop (CTN), Feb. 1-2, 2010. The CTN Workshop will expand on last year's successful meeting through in-depth presentations and discussions about how to expedite drug discovery, gain approval for new biomarkers, and comply with regulatory requirements in the U.S. and abroad. Featured seminars will cover the need for standardization in imaging trials, clinical research operating procedures, quality assurance, phantom utilization and good manufacturing practices. The CTN will host a special roundtable on the evening of Feb. 1 for leadership and senior staff at clinical research organizations. The CTN will also host sessions especially for nuclear medicine technologists about professional development opportunities in clinical trials research.

For more information: www.snm.org

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init